Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

cosibelimab

(KOH-sih-BEH-lih-mab)
A drug used to treat adults with cutaneous squamous cell carcinoma (a type of skin cancer) that has spread and cannot be cured with surgery or radiation therapy. It is also being studied in the treatment of other types of cancer. Cosibelimab binds to a protein called PD-L1, which is found on some normal cells and some types of cancer cells. Blocking this protein may help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Unloxcyt.
Search NCI's Dictionary of Cancer Terms